Patents Examined by Bao Q Li
  • Patent number: 11642407
    Abstract: Provided herein are universal prophylactic compositions for preventing infection with influenza viruses by directing the immune response to highly conserved regions of the virus. Also provided are universal therapeutic compositions for treating influenza infection by targeting the highly conserved regions. Methods for using the prophylactic and therapeutic compositions are also provided.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: May 9, 2023
    Inventor: Darrell O. Ricke
  • Patent number: 11638754
    Abstract: The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: May 2, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Andrew J. Bett, John P. Bilello, Amy S. Espeseth, Tong-Ming Fu, Marian E. Gindy
  • Patent number: 11633441
    Abstract: The invention refers to new immuno-modulated replication-efficient Vaccinia virus strain (IOVA) and its derivatives for the use in medicine.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: April 25, 2023
    Inventors: Gerd Sutter, Juan José Rojas Exposito
  • Patent number: 11633467
    Abstract: An immunogenic composition comprising at least one Norovirus antigen and at least one adjuvant which is at least one B subunit of an AB5 toxin such as cholera toxin subunit B (CTB) or the B subunit of heat-labile E. coli exotoxin LT (LTB).
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 25, 2023
    Assignee: Icon Genetics GmbH
    Inventors: Vesna Blazevic, Maria Malm, Frank Thieme, Franziska Jarczowski, Andre Diessner, Victor Klimyuk
  • Patent number: 11634478
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: April 25, 2023
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Patent number: 11629361
    Abstract: The present invention relates to adeno-associated viral vector useful for transducing adipose tissue. The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vector. The invention also relates to gene therapy methods useful for the treatment of a disease that requires the regulation of the expression levels of a gene.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: April 18, 2023
    Assignee: Universitat Autònoma de Barcelona
    Inventors: Verónica Jiménez Cenzano, Fátima Bosch Tubert
  • Patent number: 11618888
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 4, 2023
    Inventors: Tony Reid, Farah Hedjran, Shantanu Kumar
  • Patent number: 11608377
    Abstract: Methods are provided for targeting cells for depletion, including without limitation tumor cells, in a regimen comprising contacting the targeted cells with a combination of agents that modulate immunoregulatory signaling. Immunoregulatory modulating agents include (i) an agent that blockades CD47 activity; and (ii) an agent that agonizes an immune costimulatory molecule, e.g. CD137. The regimen may further comprise an agent that specifically binds to the target cell, e.g. an antibody or biologically active fragment or derivative thereof. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single immunoregulatory modulating agent is used; and the effect may be synergistic relative to a regimen in which a single immunoregulatory modulating agent is used.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: March 21, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Peter J. Schnorr, Akanksha Chhabra, Judith A. Shizuru, Irving L. Weissman, Kipp Andrew Weiskopf
  • Patent number: 11607450
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: March 21, 2023
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev
  • Patent number: 11596687
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: March 7, 2023
    Assignee: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Ian Tarpey, Iwan Verstegen, Paulus Jacobus Antonius Sondermeijer, Paul Vermeij
  • Patent number: 11596684
    Abstract: The present disclosure provides a method of dispersing agglomerated material in a preparation comprising influenza proteins. The method comprises subjecting the preparation to sonication.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: March 7, 2023
    Assignee: Seqirus Pty Ltd
    Inventors: Steven Rockman, Jesse Bodle, Nancy Guzzo-Pernell
  • Patent number: 11591615
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cells of the retinal pigment epithelium of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: February 28, 2023
    Assignee: Friedrich Miescher Institute for BioMedical Research
    Inventors: Josephine Juettner, Jacek Krol, Botond Roska
  • Patent number: 11591616
    Abstract: A recombinant myxoma virus that encodes the orfC gene of walleye dermal sarcoma virus (WDSV). The orfC gene of walleye dermal sarcoma virus (WDSV) plays a role in induction of seasonal regression of tumors caused by WDSV. This gene was isolated from WDSV and recombined into myxoma virus (MYXV orfC) for use as an oncolytic therapy. The recombinant myxoma virus can be used in oncolytic virus therapy to specifically target and lyse cancer cells without harming healthy cells in cancer patients.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: February 28, 2023
    Assignee: Colorado State University Research Foundation
    Inventors: Amy MacNeill, Sandra Quackenbush, Laura Ashton
  • Patent number: 11571471
    Abstract: The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: February 7, 2023
    Assignee: Bavarian Nordic A/S
    Inventors: Robin Steigerwald, Markus Kalla
  • Patent number: 11548931
    Abstract: A protein comprising (i) a domain of the Platelet-Derived Growth Factor receptor (PDGFR) and (ii) a domain of the Vascular Endothelial Growth Factor receptor (VEGFR) is provided. In a preferred embodiment, said domain of PDGFR and said domain of VEGFR are attached by a linker consisting of proline, alanine and serine. The domain of PDGFR and said domain of VEGFR can also be attached by a linker consisting of proline and alanine. Compositions comprising the proteins, as well as therapeutic uses thereof are also provided.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: January 10, 2023
    Assignee: XL-PROTEIN GMBH
    Inventors: Qing Dong, Michaela Gebauer
  • Patent number: 11535664
    Abstract: This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: December 27, 2022
    Assignee: IGM Biosciences, Inc.
    Inventors: Stephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
  • Patent number: 11524064
    Abstract: Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: December 13, 2022
    Assignee: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schiegl, Michael Weber, Jürgen Heindl-Wruss
  • Patent number: 11518787
    Abstract: Sequences that enhance permeation of agents into cells and/or across the blood brain barrier, compositions comprising the sequences, and methods of use thereof.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: December 6, 2022
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Fengfeng Bei
  • Patent number: 11497806
    Abstract: The present invention relates to a vaccine composition comprising an effective amount of a replication-competent controlled recombinant virus. Further encompassed are uses in immunization and methods of immunization employing compositions comprising a replication-competent controlled recombinant virus of the invention.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: November 15, 2022
    Inventor: Richard Voellmy
  • Patent number: 11484581
    Abstract: Provided herein, are methods of treating cancer in dogs using personalized cancer vaccines comprising peptides having frameshift mutations caused by errors in transcription and splicing of an mRNA.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 1, 2022
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Stephen Albert Johnston, Luhui Shen